Endeavor

New Cell Therapy Takes Advantage of a ‘Natural Killer’

Researchers study the use of natural killer cells instead of T cells in cellular immunotherapy

New Moffitt Unit is Completely Dedicated to Immune Cell Therapy

The state-of-the-art ICE-T unit will give patients and their caregivers a better treatment experience

Accidental Discovery Could Lead to Future Cancer Therapy

Researchers in Europe discover T cell that may help detect and kill several cancers

Bridging Therapy Not Recommended for All CAR T Patients

New data presented by Moffitt shows poorer outcome for patients who receive bridging therapy prior to CAR T-cell therapy.

Lumpectomy vs. Mastectomy

Each surgical treatment for breast cancer has different benefits and risks.

Moffitt Announces Launch of Immunotherapy Contract Research Organization

The new organization will provide end-to-end services for pharmaceutical and biotech companies seeking to accelerate research.

The Power of CAR T in Solid Tumor Treatment

CAR T therapy involves a patient’s own T cells that have been genetically engineered to target a patient’s own specific cancer.

Moffitt Research Moves New Immunotherapy Closer to FDA Approval

Some cancer patients may be one step closer to being treated with cells from their own tumors.

CAR T Therapy Safe for Older Patients

Moffitt’s closer look at clinical trial data could expand therapy’s use and effectiveness.